Minimal Side Effects with New Class of Breast Cancer Drugs
Final thoughts
As abemaciclib continues its approval process, people diagnosed with breast cancer will be introduced to the two CDK inhibitors already available as treatment options. While these drugs do not have any benefit to individuals who are diagnosed with HR-breast cancer, this breakthrough has still led to a deeper understanding of how cancer multiplies and spreads throughout the body, and may perhaps lead to other solutions in the future.
References
https://www.sciencedaily.com/releases/2017/07/170714071928.htm
http://www.advancedbreastcancercommunity.org/pdf/asset-library/Know_Your_Type.pdf
